Optimizing anaemia management with subcutaneous administration of epoetin

Nephrology Dialysis Transplantation

Volumn 20, Issue SUPPL. 6, 2005, Pages

  Besarab, Anatole ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

Anaemia management; Cost effectiveness; Dose; Epoetin, safety and tolerability; Subcutaneous administration

Indexed keywords

CYTOKINE; HEMOGLOBIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT;

ANEMIA; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; ERYTHROPOIESIS; EUROPE; HEALTH PRACTITIONER; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; META ANALYSIS; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; PERITONEAL DIALYSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; SYSTEMATIC REVIEW; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG ADMINISTRATION; ECONOMICS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANEMIA; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; EPOETIN ALFA; HEMATINICS; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; RED-CELL APLASIA, PURE; TREATMENT OUTCOME;

EID: 32944475656     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfh1098     Document Type: Article

References (35)

1. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-78
2. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-1178
3. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446
4. Kaufman JS. Subcutaneous erythropoietin therapy: Efficacy and economic implications. Am J Kidney Dis 1998; 32 [Suppl 4]: S147-S151
5. Locatelli F, Aljama P, Barany P et al. Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 2004; 19 [Suppl 2]: Ii1-ii47
6. Pisoni RL. Erythropoietin therapy in Europe: Results from the DOPPS. Contrib Nephrol 2002; 137: 396-402
7. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease: Update 2000. Am J Kidney Dis 2001; 37 [Suppl 1]: S182-S238
8. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002; 346: 469-475
9. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J Am Soc Nephrol 1992; 2: 1405-1416
10. Ashai NI, Paganini EP, Wilson JM. Intravenous versus subcutaneous dosing of epoetin: A review of the literature. Am J Kidney Dis 1993; 22 [Suppl 1]: 23-31
11. Bommer J, Barth HP, Zeier M et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136-143
12. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 1998; 339: 578-583
13. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF Jr for the End-Stage Renal Disease Core Indicators Work Group. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: Results from the 1998 End-Stage Renal Disease Core Indicators Project. Am J Kidney Dis 2001; 37: E36
14. Zachee P. Controversies in selection of epoetin dosages. Issues and answers. Drugs 1995; 49: 536-547
15. Alfrey CP, Rice L, Udden MM, Driscoll TB. Neocytolysis: Physiological down-regulator of red-cell mass. Lancet 1997; 349: 1389-1390
16. McGonigle RJS, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984; 25: 437-444
17. Shaw AB. Haemolysis in chronic renal failure. Br Med J 1967; 213-216
18. Macdougall IC, Roberts DE, Neubert P, Dharmasena AD, Coles GA, Williams JD. Pharmacokinetics of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Lancet 1989; 1; 425-427
19. Erslev AJ. Clinical erythrokinetics: A critical review. Blood Rev 1997; 11: 160-167
20. Taniguchi S, Dai CH, Price JO, Krantz SB. Interferon γ downregulates stem cell factor and erythropoietin receptors but not insulin-like growth factor-I receptors in human erythroid colony-forming cells. Blood 1997; 90: 2244-2252
21. Halstenson CE, Macres M, Katz SA et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50: 702-712
22. Flaharty KK, Caro J, Erslev A et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 1990; 47: 557-564
23. Muta K, Krantz SB. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin. J Cell Physiol 1993; 156: 264-271
24. Muta K, Krantz SB, Bondurant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1994; 94: 34-43
25. Locatelli F, Baldamus CA, Villa G, Ganea A, Martin de Francisco AL. Once-weekly compared with three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am J Kidney Dis 2002; 40: 119-125
26. Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B on behalf of Swedish Study Group. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: Results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014-2019
27. Grzeszczak W, Sulowicz W, Rutkowski B et al. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin β in peritoneal dialysis patients with chronic renal anaemia. Nephrol Dial Transplant 2005; 20: 936-944
28. Gallar Ruiz P, Balcke P, Martinez JM, Harris K on behalf of the Collaborative Study Group. Tolerability of the epoetin-beta multidose formulation (Reco-Pen®) in patients with renal anaemia. Clin Drug Invest 2000; 20: 151-158
29. Raftery MJ, Auinger M, Hertlovà M on behalf of the Collaborative Study Group. Safety and tolerability of a multidose formulation of epoetin beta in dialysis patients. Clin Nephrol 2000; 54: 240-245
30. Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: Phosphate-buffered epoetin alpha compared with citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998; 49: 41-44
31. Levin A, Barrett BJ, Wong G, Singer J, McMahon L, Schellenberg R. Letter from the Canadian Society of Nephrology. Issued 15 August 2002 (http://csnscn.ca/)
32. Navarro JF, Teruel JL, Marcén R, Ortuño J. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route. Scand J Urol Nephrol 1995; 29: 11-14
33. Besarab A, Reyes C, Hornberger J. Intravenous versus subcutaneous EPO: is the cost benefit acceptable? In reply. Am J Kidney Dis 2003; 41: 1122-1123
34. Fraticelli M, D'Amico M. Intravenous versus subcutaneous EPO: Is the cost benefit acceptable? Am J Kidney Dis 2003; 41: 1122
35. Hynes DM, Stroupe KT, Greer JW et al. Potential cost savings of erythropoietin administration in end-stage renal disease. Am J Med 2002; 112: 169-175